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เซลล์ตน้ก าเนิดมีเซนไคมเ์ป็นเซลล์ท่ีเกิดจากเน้ือเยื่อชั้นมีโซเดิร์ม ท่ีมีคุณสมบติัสามารถเพิ่ม
จ านวน และพฒันาไปเป็นเซลล์ของเน้ือเยื่อชั้นมีโซเดิร์มไดทุ้กชนิด อีกทั้งยงัสามารถพฒันาไปเป็น
เซลล์ของเน้ือเยื่อประสาทชั้นเอ็กโตเดิร์ม และเซลล์ของเน้ือเยื่อชั้นเอ็นโดเดิร์มบางชนิดได ้รวมทั้ง
เซลล์ตบั ปัจจุบนัเซลล์ตน้ก าเนิดมีเซนไคม์จากเน้ือเยื่อวาร์ตนัเจลล่ีท่ีเก็บได้จากสายสะดือมนุษย ์
(Human Wharton’s jelly-derived MSCs, hWJ-MSCs) ถือไดว้่าเป็นแหล่งท่ีน่าสนใจส าหรับน ามา
รักษาโรคดว้ยวิธีเซลล์บ าบดั แมว้า่นกัวิจยัหลายคนสามารถเหน่ียวน า hWJ-MSCs ไปเป็นเซลล์คลา้ย
เซลล์ตบัได ้ แต่ดว้ยสารเคมีท่ีมีราคาแพงและระยะเวลาการเหน่ียวน าท่ีนาน เป็นขอ้จ ากดัของการได้
เซลล์คลา้ยเซลล์ตบั ดงันั้น การใชส้ารเคมีชนิดอ่ืนท่ีถูกกวา่และใชเ้วลาสั้น เพื่อช่วยส่งเสริมให้ hWJ-
MSCs เปล่ียนแปลงไปเป็นเซลล์คลา้ยเซลล์ตบัเป็นส่ิงท่ีควรท า มีงานวิจยัจ  านวนมาก พบวา่ โซเดียม
บิวทิเรท (NaB) สามารถส่งเสริมการเหน่ียวน าเซลลต์น้ก าเนิดตวัอ่อนไปเป็นเซลลค์ลา้ยเซลลต์บัได ้ 
วตัถุประสงคก์ารศึกษาน้ี คือ เพื่อหาผลของ NaB ท่ีใชร่้วมกบั Epidermal growth factor (EGF) 
และ Basic fibroblast growth factor (bFGF) ต่อการเหน่ียวน า hWJ-MSCs ไปเป็นเซลล์คลา้ยเซลล์ตบั
ของเน้ือเยื่อชั้นเอ็นโดเดิร์ม นอกจากน้ียงัตรวจสอบความเขม้ขน้ท่ีเหมาะสมของ NaB ท่ีใช้ร่วมกบั 
EGF และ bFGF ก่อนการเหน่ียวน า hWJ-MSCs ไปเป็นเซลล์ตบั โดยใชข้อ้มูลการแสดงออกของยีนท่ี
เก่ียวขอ้งกบัการพฒันาไปเป็นเซลล์ในชั้นเอ็นโดเดิร์มดว้ยวิธี qPCR และการแสดงออกของโปรตีน 
SOX17 ดว้ยวิธี Immunocytochemistry ท าการเปรียบเทียบการเหน่ียวน า hWJ-MSCs ไปเป็นเซลล์
คลา้ยเซลล์ตบัระหวา่งกลุ่มน ้ ายาเหน่ียวน าเซลล์ตบัท่ีเติม NaB ช่วงก่อนการเหน่ียวน าไปเป็นเซลล์ตบั
ร่วมกบั EGF และ bFGF เป็นเวลา 72 ชัว่โมง (Hepatogenic medium + NaB pre-treated) และกลุ่ม
น ้ายาเหน่ียวน าเซลล์ตบัท่ีไม่เติม NaB ช่วงก่อนการเหน่ียวน าไปเป็นเซลล์ตบัร่วมกบั EGF และ bFGF 
เป็นเวลา 72 ชัว่โมง (Hepatogenic medium - NaB pre-treated) โดยตรวจสอบการเปล่ียนแปลงไปเป็น
เซลล์คลา้ยเซลล์ตบัดว้ยวิธี Immunocytochemistry, qPCR, Periodic acid-Schiff (PAS) reaction และ 
Urea production assay ของวนัท่ี 3, 10, 17 และ 24 ของการเหน่ียวน า นอกจากน้ียงัตรวจสอบผลของ 
NaB ต่อการยบัย ั้งการท างานของเอนไซม ์Histone deacetylase inhibitor 1  
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 Mesenchymal stem cells (MSCs) are multipotent mesoderm-derived cells that 
can self-renew and differentiate into all mesodermal, and some neuroectodermal and 
endodermal progenies include hepatocytes. Nowadays, human Wharton’s jelly-derived 
MSCs (hWJ-MSCs) are an attractive source for cell-based therapy. Although, many 
investigators successfully used hWJ-MSCs to differentiate into hepatocyte-like cells, 
however, high chemical costs and long period of time for induction are the limitation 
factors. Therefore, the used of other cheaper chemical and less-time consuming to 
promote hWJ-MSCs into hepatocyte-like cells are needed. With many evidences, 
sodium butyrate (NaB) can promote embryonic stem cells (ESCs) differentiation toward 
hepatocyte-like cells.  
The aim of this study was to verify the effect of NaB in combination with 
Epidermal growth factor (EGF) and Basic fibroblast growth factor (bFGF) on hWJ-
MSCs transdifferentiation toward hepatoendodermal lineage. Furthermore, the optimal 
concentration of NaB in combination with EGF and bFGF right before hepatogenic  
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CHAPTER I 
INTRODUCTION 
 
1.1 Background 
Liver is an important and largest organ that can produce metabolites and 
detoxify toxic substances in our body. Hepatocytes are cells in the liver that are 
gradually being destroyed from the toxic substances which lead to liver failure and 
death at the end-stage of liver diseases (reviewed in Gordillo, Evans and Gouon-
Evans, 2015). The treatments of orthotropic liver organ and cells transplantations have 
recently been pioneered for these patients. Nevertheless, the inadequate and the 
shortage of organ donors and low quality cultivation of hepatocytes are the main 
problems for these kinds of treatments (Zaret and Grompe, 2008; Dhawan et al., 
2010). The limitation of these treatments needs some new alternative therapeutic 
approaches. Presently, stem cell technology has been considered as a promising tool in 
cell-based therapy. The field of mesenchymal stromal cells (MSCs) has been getting 
high attention.  
The fact that the used of MSCs have less ethical concern and fewer 
teratomatous formation when compared with pluripotent embryonic stem cells (ESCs) 
makes them a promising tool.  Also, MSCs have shown some attractive qualities; such 
as plastic attachment, self-renewal, positive expression of unrestricted MSCs markers 
and tri-mesodermal differentiation such as osteoblasts, chondrocytes and adipocytes 
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(Dominici et al., 2006). The MSCs can be isolated from both fetus and postnatal 
tissues such as bone marrow, adipose tissue, amniotic fluid, umbilical cord blood and 
umbilical cord tissue (Romanov et al., 2005; Troyer and Weiss, 2008; Witkowska-
Zimny and Wrobel, 2011). These entire reasons make MSCs became a good candidate 
for therapeutic purpose in clinical applications. 
Umbilical cord Wharton’s jelly tissue is the richest and attractive source of 
MSCs. It can be obtained through noninvasive collection. It also has low 
immunogenicity when compared to other adult MSC tissue sources (Karahuseyinoglu 
et al., 2007). The characteristics of Wharton’s jelly-derived MSCs (WJ-MSCs) similar 
to bone marrow-derived MSCs (BM-MSCs) are prototype. They can differentiate into 
hepatocyte-like cells of endodermal lineage which make them an alternative choice 
for an extensive hepatocyte-like cells differentiation study (Baksh, Yao and Tuan, 
2007; Wang et al., 2004). The derivation of MSC-derived hepatocyte-like cells in 
vitro mimics the embryonic hepatoendodermal development in vivo and the ESCs 
differentiation in vitro studies of animal and human development models (reviewed in 
Gordillo, Evans and Gouon-Evans, 2015). Nowadays, many hepatogenic 
differentiation protocols of hWJ-MSCs in vitro have been successfully achieved 
(Campard et al., 2008; Zhang et al., 2009; Zhao et al., 2009; Anzalone et al., 2010; 
Yoon et al., 2010; Prasajak and Leeanansaksiri, 2013; An et al., 2014; Borhani-
Haghighi et al., 2015); however, more attractive protocols needed to be developed to 
obtain homogenous hepatocyte-like cells population with less-time consuming and 
cheaper chemicals.  
Sodium butyrate (NaB) is a small molecule, short chain butyric acid, which in 
a fatty acid in its sodium salt formed from dietary fibers fermentation of anaerobic 
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bacteria in alimentary tract (Ghosh et al., 2012). It plays a key role as histone 
deacetylase inhibitor (HDACi) in anti-tumor drug (Chen, Ghazawi, Bakkar, and Li, 
2006), neurological disorder treatments (Bourassa et al., 2016) and stem cell 
differentiation at physiological concentrations (Vrba, Trtkova and Ulrichova, 2011; 
Shah et al., 2013). It has been used successfully and consistently in ESCs 
differentiation to hepatocyte-like cells (Rambhatla et al., 2003; Sharma et al., 2006; 
Zhou et al., 2007; Mizumoto et al., 2008; Hay et al., 2008; Ren et al., 2010; Zhou et 
al., 2010; Cao et al., 2010; Yan et al., 2011). Therefore, these evidences made NaB as 
an appropriate chemical of choices to promote MSC differentiation into hepatocyte-
like cells. However, the combination of NaB with growth factors, such as activin A 
(Mizumoto et al., 2008) or bFGF and BMP4 (Cao et al., 2010) can promote ESCs 
differentiation into hepatocyte-like cells greater than NaB treatment alone. Therefore, 
it is important to find out in details of the combination of NaB and growth factors that 
can promote MSC differentiation into hepatocyte-like cells.  
The aim of this study was to verify the approach of hWJ-MSCs differentiation 
into functional hepatocyte-like cells that expressed endodermal, hepatoblast and 
hepatocyte-like features. To achieve this goal, the combination of NaB with EGF and 
bFGF in the pre-treatment step for 72 h before hepatogenic differentiation from hWJ-
MSCs with other maturation factors (Campard et al., 2008), such as HGF, bFGF and 
nicotinamide (in the differentiation step) and OSM, dexamethasone and ITS (in the 
maturation step) were investigated. This protocol could provide an alternative source 
of hWJ-MSCs-derived hepatocyte-like cells for stem cell-based therapy in patients 
with end-stage liver diseases.  
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1.2  Research objectives 
1.2.1 To isolate and characterize hWJ-MSCs from human umbilical cord 
Wharton’s Jelly tissue. 
1.2.2 To investigate the effect of NaB on HDACi through HDAC1 gene and 
protein expressions using immunocytochemistry, Western Blot and RT-qPCR 
analyses.  
1.2.3 To determine the optimum concentration of NaB on cell viability, 
endodermal and hepatogenic transdifferentiate of hWJ-MSCs in vitro. 
1.2.4 To characterize HI-hWJMSCs in vitro using Immunocytochemistry, 
qRT-PCR and biochemical function analyses. 
 
1.3  Research hypotheses 
1.3.1 Under defined culture system, MSCs could be isolated and expanded 
from human umbilical cord Wharton’s jelly tissue and should exhibit typical 
properties of MSCs, which are self-replicate, immunophenotyping, as well as their 
ability to tri-mesodermal lineages differentiation in in vitro. 
1.3.2 The optimized NaB pre-treatment could promote endodermal-related 
genes and protein expressions through partially HDAC1 inhibition in the present of 
EGF and bFGF supplementation and enhances hepatogenic differentiation of hWJ -
MSCs in in vitro. 
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1.4  Scope of the study 
1.4.1 Under defined culture system, MSCs were isolated and expanded from 
human umbilical cord Wharton’s jelly tissue. MSC signatures from this tissue were 
examined by the expression profile of surface antigens (e.g. CD34, CD73, CD90 and 
CD105). Tri-mesodermal lineages differentiation of hWJ-MSCs was performed by the 
differentiated osteoblast, chondrocyte and adipocyte.  
1.4.2 The optimized NaB pre-treatment were checked from cell viability and 
endodermal-related genes (CXCR4, SOX17, and GATA6) and SOX17 protein 
expressions through partially HDAC1 inhibition in the present of EGF and bFGF 
supplementation before hepatogenic differentiation. The differentiated hWJ-MSCs 
with NaB pre-treatment can be differentiated into hepatoblast-like cells (AFP and 
HNF3β) and hepatocyte-like cells (CK18 and ALB) greater than the differentiated 
hWJ-MSCs without NaB pre-treatment. Besides, functional mature hepatic properties 
were evaluated by Periodic acid-Schiff (PAS) reaction and urea production assays. 
  
 
 
 
CHAPTER II 
LITERATURE REVIEW 
 
2.1  Liver 
 The liver is the largest internal gland and consists of four poorly defined lobes 
of the human body. It has providing many important metabolic, exocrine and 
endocrine functions, such as bile production, dietary compound metabolism, 
detoxification, blood glucose levels regulation through glycogen storage, blood 
homeostasis control by blood clotting factors and serum protein albumin (ALB) 
secretion. The structural and functional unit of the liver is the hepatic lobule, which 
consists of polygonal-shaped hepatic cord of liver cells arranged around a central vein 
that is a terminal branch of a hepatic vein. Branches of hepatic artery, portal vein, 
together with a bile duct (Fig. 2.1A), form the classic portal triad found in the portal 
spaces (reviewed in Zorn and Wells, 2007; Gordillo, Evan and Gouon-Evans, 2015). 
2.1.1 Cell types and their organization of the hepatic lobule 
 The mature liver contains multiple cell types, including hepatocytes 
and cholangiocytes are derived from the embryonic endoderm, whereas the 
endothelial, stellate and Kupffer cells are of mesodermal origin (Fig. 2.1B). 
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Figure 2.1    Liver structure and cell types. (Gordillo, Evan and Gouon-Evans, 2015) 
(A) Structure of the hepatic lobule and portal triad.  
(B) Organization of the hepatic lobule and cell types in the mature liver. 
  
2.1.1.1 Hepatocytes and cholangiocytes 
   Hepatocytes are the functional metabolic, exocrine and 
endocrine cells of the hepatic lobules that accounting for approximately 80% of the 
mass of the adult organs. A hepatocyte has two distinct domains: basolateral and 
apical domains. The basolateral domain with microvilli was separated from blood 
circulating of hepatic sinusoid by space of Disse, which enables an exchange 
metabolites and toxins between blood and hepatocyte. Representation of the bile pole 
of hepatocyte, an apical domain, secreted bile out into the bile canaliculi (grooves in 
the cell surface) that flow through the intra hepatic bile duct (IHBD) to the extra 
hepatic bile duct (EHBD) and stored into the gall bladder before release into the 
duodenum (reviwed in Zorn and Wells, 2007; Gordillo, Evan and Gouon-Evans, 
2015).  
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  2.1.1.2 Endothelial and Kupffer cells 
  In the liver, endothelial and Kupffer cells line the hepatic 
sinusoid. Endothelial cells have a fenestrated cytoplasm associated with a 
discontinuous basal lamina. Kupffer cells are the differentiated phagocytic cell derived 
from monocytes (reviewed in Gordillo, Evan and Gouon-Evans, 2015). During liver 
organogenesis, endothelial cells are important for hepatic specification and hepatoblast 
expansion from murine endoderm cells and ESC-derived endoderm cells (Han et al., 
2011). No evidence of Kupffer cells for hepatic differentiation; however, they play an 
important role in liver regeneration during chronic injury by influencing the invasive 
behavior of liver progenitor cells (Boulter et al., 2012). 
 2.1.1.3 Stellate cells 
  Stellate (Ito) cells are the major mesenchymal component in the 
liver that located in the space of Disse. They are the major vitamin A reservoir when 
quiescent state, but when injury or infection occurred, they were activated into α-
smooth muscle actin (αSMA)-expressing myofibroblast-like cells differentiation that 
extracellular matrix (ECM) deposits capacity and directing temporary fibrotic scar 
formation (Puche et al., 2013).  
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2.2  Liver diseases and their therapies 
 2.2.1  Liver diseases 
  Liver or hepatic diseases are describing all the potential problems 
because the liver performance to fail theirs designated functions. More than 75% of 
liver tissue needs to be affected before a decrease in function occurs. They occurred 
from many causes, such as infection and inflammation, alcoholism, genetic defects 
and tissue injury from toxic drugs or compounds. Common symptoms of liver diseases 
include weakness, fatigue, weight loss, nausea, vomiting and jaundice. However, since 
there are a variety of liver diseases, the symptoms tend to be specific for that illness 
until late-stage liver disease and liver failure occurs (Wedro, 2011). The stages of liver 
diseases are classified by the American Association for Clinical Chemistry (AACC) of 
the US groups in 2011. Initially, the higher dosage and time exposure of toxins and 
drugs including alcoholic over-uptake, leads to lipid formation in the liver, known as 
fatty liver, caused by both alcoholic and non-alcoholic cases. Then, the lesions are 
progressed to inflammation of reversible fibrous scar tissue of the liver, hepatitis. 
Unfortunately, the advanced fibrous scar tissue results in irreversible regeneration of 
liver tissue and function, known as cirrhosis. In some case, it could progress to 
hepatocarcinoma and lead to liver failure and death from other complications (ascites, 
hepatic encephalopathy, and portal hypertension) at late-stage liver diseases.  
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 2.2.2  Regenerative therapies 
  As mentioned above, approximately three quarters of liver tissue are 
destroyed that affect irreversible or difficult reversible of normal physiological liver 
functions. Normally, treatment of liver diseases depends on the severity of disorders or 
symptoms. It has not been only relieved with medicine, but also the operation to cure 
may be used. For instance, ascites fluid and portal hypertension are cured by removed 
excess fluid and operation with minimize the risk of bleeding. Nevertheless, 
orthotropic liver transplantation is the final choice of the effective treatment of these 
diseases (Wedro, 2011). However, the shortage time and the inadequate of liver organ, 
high costs and life-long requirement for immunosuppression were limited to use of 
this therapy (Dhawan, Puppi, Hughes, and Mitry, 2010). The field of stem cell therapy 
has raised great hope for improving the treatment of liver diseases. Due to, they may 
retain the potential to transdifferentiation from one phenotype to another type, 
presenting exciting possibilities for cellular therapies (Talѐns-Visconti et al., 2006). 
Therefore, a promising source of stem cells for the end-stage of liver diseases 
treatment could be challenged. 
 
2.3  Mesenchymal stem cells (MSCs) 
 The first identification of mesenchymal stem cells (MSCs) occurred from the 
minor population of bone marrow in 1961 (Friedenstein, et al., 1961). After this 
discovery occurred, the multipotent differentiation potential of tri-mesodermal 
lineages (Fig. 2.2) also occurred into osteoblasts, chondrocytes and adipocytes 
(Pittenger, et al., 1999). Otherwise, MSCs have also been isolated from adipose tissue 
  
11 
 
(Fraser et al., 2008), dental pulp (Liu et al., 2009), umbilical cord blood (Phuc et al., 
2011) and Wharton’s jelly of umbilical cord tissue (Wang et al., 2004). In 2006, the 
Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cellular Therapy (ISCT) had established the MSCs definition and changed the name 
from mesenchymal stem cells to mesenchymal stromal cells. Firstly, MSCs have been 
characterized by their plastic adherent growth and subsequent expansion under 
appropriate culture conditions. Secondly, they must express their protein surface 
markers CD73, CD90 and CD105, and lack expression of CD45, CD34, CD14 or 
CD11b, CD79a or CD19 and HLA-DR surface molecules. Thirdly, they must 
differentiate into osteoblasts, chondrocytes and adipocytes in vitro under appropriate 
culture conditions (Dominici et al., 2006). With the multipotent characteristics, 
abundant source of cells, and little ethical controversy, MSCs could be more 
appropriate source of cell for liver diseases treatment. 
 
Figure 2.2 Three minimal criteria recommended for identification of MSCs. 
(Modified from Application note of PromoCell GmbH Company, 
Germany, 2015).  
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2.4  Human umbilical cord and human Wharton’s jelly-derived 
stem cells (hWJ-MSCs) 
Wharton’s jelly (WJ) is proteoglycans and mucopolysaccharides-rich 
connective tissue that surrounded two arteries and a vein (Fig. 2.3) of umbilical cord 
of extra-embryonic membrane (Karahuseyinoglu et al., 2007). Naturally, WJ supports 
the structure of umbilical blood vessels during pregnancy. The cell component is 
presented by mesenchyme-derived cells, such as fibroblasts, myofibroblasts, smooth 
muscle cells, and MSCs. Presently, the MSCs from umbilical cord include cells 
derived from the total umbilical cord or its different sections; perivascular, 
intervascular, and subamnion zones of WJ and subendothelial layer, but not from 
umbilical cord lining or inner blood vessel walls (Bongso and Fong, 2013). 
Thomas Wharton discovered WJ tissue in 1956. This tissue was considered 
medical waste with no scientific value. Until McElreavey and collaborates isolated 
fibroblast-like cells from WJ and characterized them (McElreavey, Irvine, Ennis, and 
McLean, 1991). These fibroblast-like cells were proved to be MSCs as they expressed 
CD29, CD44, CD51, CD73, and CD105, lacked expression of CD34 and CD45, and 
were able to differentiate into cells of the adipogenic and osteogenic lineages (Wang et 
al., 2004). According to previous report, only 0.001-0.01% of MSCs presented in bone 
marrow stromal, while for MSCs of umbilical cord tissue it reached 0.2-1.8% 
(Wegmeyer, et al., 2013). Besides, MSCs of umbilical cord tissue have higher 
proliferative potential, easily accessible and abundant than MSCs from other sources; 
adipose tissue (postnatal), placenta and amniotic membrane (neonatal sources) (Li et 
al., 2014; Shaer, Azarpira, Aghdaie, and Esfandiari, 2014). Additionally, several 
publications reported the successful in vitro differentiation of WJ-derived MSCs (WJ-
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MSCs) into various specific cell types beyond their mesodermal lineage, such as glial 
cells and neurons (Mitchell et al., 2003), dopaminergic neurons (Fu et al., 2006) in 
ectodermal lineage and insulin-producing cells (Chao et al., 2008; Wang et al., 2011) 
as well as hepatocyte-like cells (Zhang, Lie, and Wei, 2009) in endoderm lineage. 
Therefore, these benefits bring up umbilical cord tissue as a potential adult stem cell 
reservoir for further clinical application in each individual. 
 
Figure 2.3 Cross section of normal human umbilical cord. A: artery; V: vein; WJ: 
Wharton’s jelly. Hematoxylin and eosin staining, scale bar = 200 𝜇m. 
(Arutyunyan, Elchaninov, Makarov, and Fatkhudinov, 2016).  
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2.5  Hepatogenesis and their cell signaling pathway regulation  
With highly complexity and organization of liver developmental processes 
from embryo to adult can be divided into several distinct stages based on molecular 
and functional properties of human and animal models in vivo and ESC-derived 
hepatocyte-like cells in vitro studies. Many evidences of hepatogenesis are 
evolutionarily conserved and occur through a progressive series of mutual tissue 
interactions between the embryonic endoderm and nearby mesoderm. Nowadays, 
liver development duration is identifiable in zebrafish, mouse and human models 
(Table 2.1) (reviewed in Gordillo, Evan and Gouon-Evans, 2015). 
Table 2.1 Interspecies comparison of the timeline of liver development (reviewed in    
Gordillo, Evan and Gouon-Evans, 2015). 
Developmental stages Zebrafish(h) Mouse (d) Human (d) 
1. Endoderm 6 7.5 < 23 
2. Liver diverticulum:  
 hepatoblast specification 
18-24   8.5-9.0 23-26 
 
3. Liver bud:  
hepatoblast migration and 
proliferation 
24-28 9.5 26-32 
4. Liver bud outgrowth:   
proliferation of hepatoblasts 
and sinusoid expansion 
48-120 9.5-14.5 31-56 
 
5. Hepatocyte and 
cholangiocyte differentiation 
24-48 13.5 (initiation) to 
18.5 (termination)     
56-58 (initiation) to 
∼210 (termination) 
6. Gestation duration NA 18-19   266-280 
ABBREVIATION: NA: not applicable, h: hour, d: day. 
  
15 
 
According previous mentioned above, hepatocytes and cholangiocytes are 
derived from endoderm that emerges from the anterior primitive streak of the 
gastrulating embryo. Four key major steps model during fetal liver development are 
summarized following mentioned below (Fig. 2.4) (reviewed in Gordillo, Evan and 
Gouon-Evans, 2015).  
(A) Endoderm specification; activation of Activin/Nodal signaling, is a 
transforming growth factor β (TGFβ) family, that signal through activin receptors 
type I and II, and the co-receptor Cripto (Teratocarcinoma-derived growth factor-1; 
Tdgf1) to drive mesendoderm formation from the embryonic epiblast lineage in 
Xenopus (Hyde and Old, 2000; Xanthos et al., 2001) and zebrafish (Schier and 
Talbot, 2005; Fan et al., 2007), while in mice uncleaved Nodal precursor in the 
epiblast activates bone morphogenic protein 4 (BMP4), and then activates Wingles 3 
(Wnt3) to maintain high levels of Nodal selectively (Ben-Haim et al., 2006). 
Bipotential mesendoderm cells segregate into brachyury-expressing (BRY
+
) 
mesoderm and definitive endoderm (DE). With low Activin/Nodal doses inducing 
mesoderm and higher doses inducing endoderm (Zorn and Wells, 2007). The 
prospective foregut endoderm maintains expression of the pioneer transcription 
factors forkhead box protein A2 (FOXA2) or hepatocyte nuclear factor-3β (HNF3β) 
and GATA-binding factor 4/6 (GATA4/6), denoted GATA. Recently, C-X-C 
chemokine receptor type 4 (CXCR4) can be used to distinguish early visceral and 
definitive endoderm in both human and mouse ESCs (D’Amour et al., 2005; 
Yasunaga et al., 2005; Takenaga, Fukumoto, and Hori, 2007; Teo et al., 2011).), as 
well as in the differentiated hWJ-MSCs into DE cells (Allahbakhshi et al., 2013; An 
et al., 2014). 
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(B) Endothelial cells influence during liver morphogenesis; studies of ESC 
cultures suggest that the DE includes a subset of kinase insert domain receptor-
expressing (KDR
+
) progenitors that generate and support the development of hepatic 
cells; they can also give rise to CD31-expressing or platelet endothelial cell adhesion 
molecule 1-expressing (PECAM1
+
) endothelial cells. 
(C) Hepatic specification from hepato-pancreatic progenitors; the graded 
activity of Wnt, fibroblast growth factor (FGF) and BMP signaling patterns the 
endoderm along the anterior-posterior (A-P) axis (Horb and Slack, 2001; Kimura et 
al., 2007), to generate posterior foregut precursors with hepato-pancreatic potential 
that can be divided from anterior foregut, deriving lung and thyroid and midgut-
hindgut, deriving intestine progenitors. Foregut DE generates a bipotential hepato-
pancreatic progenitor; SRY (sex determining region Y chromosome)-box 17-
expressing (SOX17
+
), hematopoietically-expressed homeobox-expressing (HHEX
+
), 
and GATA
+
 that produces both pancreatic and duodenal homeobox 1-expressing 
(PDX1
+) pancreatic progenitors and HNF1β+, HNF4α+, PDX1– hepatoblasts.  
Hepatoblast expansion is regulated by interactions with surrounding 
endothelial and mesenchymal cells in the septum transversum (Shin and Monga, 
2013). Wnt signaling promotes the proliferation of hepatoblasts (Goessling et al., 
2008; McLin et al., 2007), acting in cross-talk with hepatocyte growth factor (HGF) 
by the phosphorylation of β-catenin through HGF receptor (HGFR) or tyrosine-
protein kinase methionine proto-oncogene (c-MET) or by nuclear translocation and 
FGF signaling (Berg et al., 2007; Schmidt et al., 1995). Besides, hepatoblasts are 
marked by the expression of both hepatocyte (alpha-fetoprotein (AFP), albumin 
(ALB), cytokeratin 18 (CK18)) and cholangiocyte (CK19) transcript and protein 
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markers. Additionally, delta homolog 1 (DLK1), epithelial cadherin (E-cadherin), 
epithelial cell adhesion molecule (EpCAM), CD133 or prominin 1 (PROM1) and the 
hepatocyte-specific antigen (HepPar1) are also expressing in hepatoblasts (Haruna et 
al., 1996; Terrace et al., 2007; Wauthier et al., 2008). 
(D) Hepatic commitment from hepatoblast; hepatoblast differentiation into 
cholangiocytes and hepatocytes, and the final maturation of these cells, is regulated 
by a wide array of signaling pathways that display complex cross-regulation. 
Signaling by HGF, oncostatin M (OSM), and glucocorticoid hormones act in a 
reinforcing to promote hepatocyte maturation (Shin and Monga, 2013), while 
cholangiocyte induction activate TGFβ, Notch, BMP, FGF, Wnt, and Hippo/Yap 
signaling pathway. These pathways also influence the 3D structural organization of 
the liver and define its zonal characteristics. The hepatoblast is a bipotential 
progenitor for both cholangiocytes (bile duct cells; HNF6
+
, SOX9
+, HNF1β+) and 
hepatocytes (Prospero homeobox protein 1-expressing; PROX1
+
 and HNF4α+). 
Besides, CCAAT enhancer binding protein (C/EBP)-α, -β are also expressing in 
mature hepatocyte (reviewed in Snykers et al., 2009). In human ESC (hESC) 
differentiation cultures, KDR-expressing progenitors for hepatoblast-like cells occur 
concomitantly with committed hepatic cells and promote their maturation, as 
indicated by ALB expression (Goldman et al., 2013). Note, in many cases, such as 
for FoxA and GATA factors, they also continue to be expressed and also function at 
later stages.  
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Figure 2.4 Bipotential progenitors progressively generate hepatic lineages. (Gordillo, 
Evan and Gouon-Evans, 2015) 
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2.6  Hepatogenic differentiation of human MSC potential 
Nowadays, many evidences revealed extra-hepatic MSC-derived hepatocytes 
are driven by complex processes have been published in recently, based on cellular 
stimulation with exogenous cytokines, growth factors, hormones, co-culture with 
fetal or adult hepatocytes, challenging with conditioned media from cultured 
hepatocytes, two- (2D) or three-dimensional (3D) matrices to favor differentiation 
(reviewed in Snykers et al., 2009; Anzalone et al., 2010; Ye et al., 2015). Presently, 
MSCs obtained from various sources, such as human bone marrow-derived MSCs 
(hBM-MSCs), human umbilical cord blood-derived MSCs (hUCB-MSCs), human 
adipose tissue-derived stem cells (hADSCs), human placenta-derived MSCs (hPL-
MSCs), human amniotic membrane-derived MSCs (hAM-MSCs), human amniotic 
fluid-derived MSCs (hAF-MSCs), hWJ-MSCs and human dental pulp-derived SCs 
(hDPSCs), have been demonstrated to process hepatic differentiation potential which 
allows them to differentiate into hepatocyte-like cells under culture conditions in 
vitro (Lee et al., 2004; Seo et al., 2005; Chien et al., 2006; Talѐns-Visconti et al., 
2006&2007; Banas et al., 2007; Tamagawa et al., 2007; Zheng et al., 2008; Campard 
et al., 2008; Zhang, Lie and Wei, 2009; Zhao et al., 2009; Ishkitiev et al., 2010; 
Pournasr et al., 2011; Lee et al., 2012; Prasajak and Leeanansaksiri; 2013).  
The first report of MSC differentiation into functional hepatocyte-like cells 
was successfully studied by Lee and collaborates in 2004, by using hBM-MSCs and 
hUCB-MSCs. They cultured into 2-step differentiation paradigm with EGF and 
bFGF pre-conditioned for 48 h. Then, they induced MSCs into hepatoblast-like cells 
by using bFGF, HGF and nicotinamide, and following exposed OSM, insulin-
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transferrin-selenium (ITS), and dexamethasone in order to differentiate into 
functional mature hepatocytes for 6 weeks. Nevertheless, previous study showed the 
pioneer discovered hepatic differentiation cocktail of MSC-like cells (multipotent 
progenitor cells; MAPCs), they lack expression of CD45 (CD45
-
), and glycophorin A 
(GlyA
-
), acquired the ability to undergo hepatocyte-like cell differentiation by 
optimized various cytokines, growth factors, hormones and chemicals. However, 
only FGF4 and HGF can induce MAPCs into hepatocyte-like cells, the differentiated 
cells were not homogenous hepatic characteristic population (Schwartz et al., 2002). 
Another report revealed hBM-MSCs also successfully generated hepatocyte-like cell 
differentiation by cultured in FGF-4 and HGF, and following cultured in the cocktail 
of HGF, ITS and dexamethasone in medium of differentiation (Pournasr et al., 2011). 
Besides, other reports also were successfully acquired functional hepatocyte-
like cell-derived MSC differentiation from other sources by some modified from 
previous protocol, such as hADSCs, hPD-MSCs, and hDPSCs. Firstly, Talѐns-
Visconti et al. (2006) revealed hADSCs could differentiate into functional 
hepatocyte-like cells for 21 days with EGF and bFGF pre-induction for 48 h, by 
demonstrated for the first time that the differentiated hADSCs expressed drug-
metabolizing enzymes similar to hBM-MSCs, such as CYP2E1 and CYP3A4. 
Secondly, Talѐns-Visconti et al. (2007) also demonstrated hADSCs could 
differentiate into hepatocyte-like cells by cultured in both two protocols of some 
dependently 2-step differentiation paradigms for 14 days after pre-conditioned with 
EGF and bFGF for 48 h; protocol A, they cultured in serum-free hepatogenic 
medium supplemented with bFGF, HGF and nicotinamide in both 2 steps, while 
protocol B they cultured in medium supplemented as same in step-1, and differs at 
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step-2 by added OSM, ITS and dexamethasone. Thirdly, another group performed 
after hADSCs exposed FGF1, FGF4 and HGF, and then following exposed OSM and 
dexamethasone, they could also differentiate toward functional hepatocyte-like cells 
in vitro (Banas et al., 2007). Fourthly, Saulnier et al. (2010) revealed the molecular 
mechanism underlying the hepatic differentiation of hADSCs by exposed HGF and 
FGF-4 in the early stage and the mixture of OSM with nicotinamide in the maturation 
stage. They indicated the transition of molecular pathway occurs during 
differentiation from mesenchymal to epithelial lineage that is a feature of 
hepatocytes. Fifthly, Chien and coworkers (2007) showed hPL-MSCs could also 
differentiate into hepatocyte-like cells by cultured in ITS, linoleic acid, bovine serum 
albumin, dexamethasone, ascorbic acid, EGF, and platelet-derived growth factor-BB 
(PDGF-BB) for 16 h, then they following cultured in HGF and FGF-4 of hepatogenic 
medium until day 28. Sixthly, human umbilical matrix-derived stem cells (hUC-
MSCs or hWJ-MSCs) could also differentiate into functional hepatocyte-like cells, 
revealed by Campard and collaborates (2008). They cultured hUC-MSCs in bFGF, 
HGF, nicotinamide and dexamethasone at step-1 after pre-conditioned with EGF and 
bFGF for 48 h, and then they following cultured in OSM, ITS and dexamethasone for 
21 days. Finally, Zhao, et al. (2009) and, Prasajak and Leeanansaksiri (2013) 
performed that hWJ-MSCs could differentiate into more functional hepatocyte-like 
cells by cultured into 2-step differentiation paradigms by increased concentration of 
HGF and OSM, respectively, in independently two hepatogenic differentiation 
protocols without EGF and bFGF pre-treated for 48 h.  
Interestingly, previous simple protocol of one-step hepatic differentiation 
revealed hADSCs could differentiate into hepatocyte-like cells by exposed dimethyl 
  
22 
 
sulfoxide (DMSO), HGF and OSM in vitro (Seo et al., 2005). Besides, hAM-MSCs 
could also differentiate into functional mature hepatic lineage after treatment with 
induction medium as 10% FBS, HGF, bFGF, OSM, and dexamethasone (Tamagawa, 
Oi, Ishiwata, Ishikawa, and Nakamura, 2007). Additionally, hWJ-MSCs were 
induced with 1% FBS, HGF, and FGF-4; the differentiated cells expressed hepatic 
specific markers both at gene and protein levels, and functional hepatic 
characteristics, such as stored glycogen and had ability to uptake LDL (Zhang, Lie, 
and Wei, 2009). 
More recently, Kazemnejad and colleagues (2009) reported the use of 3D 
biocompatible nanofibrous scaffold to enhance hepatic differentiation of hBM-MSCs. 
The cells grown on 2D and 3D conditions were stimulated by HGF, OSM, and 
dexamethasone for 3 weeks. The differentiated cells grown on 3D matrix showed 
increased expression of hepatic markers and functions with respect to cells 
differentiated on a 2D culture system. However, other scaffolds also used to enhance 
hepatogenic differentiation of MSC from murine, such as alginate scaffold (Lin et al., 
2010), collagen-coated poly (lactic-co-glycolic acid) (C-PLGA) scaffold (Li et al., 
2010), and synthetic extracellular matrix ultraweb nanofibers (Piryaei, Valojerdi, 
Shahsavani, and Baharvand, 2011).  
Another procedure, using co-culture MSC from animals with hepatic stellate 
cell (HSC) and mature hepatocytes, by assumed that secreting factors from their cells 
induced hepatic differentiation of MSC (Antoine et al., 2007; Deng et al., 2008; 
Qihao et al., 2007; Gu, Shi, Zhang, and Ding, 2009). Few years, hWJ-MSCs could 
differentiate into hepatocyte-like cells by premeabilization of them in the presence of 
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HepG2 cell extract at the first time (Borhani-Haghighi, Talaei-Khozani, Ayatollahi, 
and Vojdani, 2015).  
The first successful of MSC differentiation toward endoderm-like cells was 
reported by Allahbakhshi and coworkers (2013). They used hWJ-MSCs exposed with 
low and high concentrations of activin A (20 and 100 ng/ml) and Wnt3a (25 ng/ml) 
or combination for 3 days. The differentiated cells could highest express DE (SOX17 
and CXCR4) and anterior DE transcripts, (FOXA2 and CER) at low concentration of 
activin A (20 ng/ml) in combination with Wnt3a for 24 h and followed step-2 they 
exposed low concentration of activin A (20 ng/ml) for 48 h. Presently,  utilizing 3D 
spheroid formation could efficiently enhance WJ-MSCs into DE cells, by expressing 
DE transcripts and proteins (CXCR4, SOX17 and FOXA2) (Madhound et al., 2016).  
 
2.7  Histone acetylation of epigenetic modification machinery 
Epigenetic modifications of the histone N-terminal tails are subjected to 
various post-translational modifications, including acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, adenosine diphosphate (ADP)-
ribosylation and glycosylation  (Izzo and Schneider, 2010; Lee, Smith and Shilatifard, 
2010). Nevertheless, histone acetylation is the best-understood posttranslational 
histone modification (reviewed in Snykers et al., 2009). Normally, balancing of 
histone acetylation of chromatin structure and target gene expression was regulated by 
two opposing enzyme activities, such as histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) (Figure 2.5). HATs catalyze the acetylation of core histones 
through the addition of an acetyl group to the lysine residue (K) on the N-terminus of 
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histones. These phenomenons, to neutralize their positive charges subsequently 
leading to a relaxed chromatin structure, which is more accessible to the transcription 
machinery. Another class of enzymes, HDACs, is expressed in all eukaryotic cells, 
and their activity is essential for cell proliferation, differentiation and homeostasis, 
catalyzes deacetylation through the hydrolysis of an acetyl moiety from the K, leading 
to chromatin condensation and transcriptional repression (reviewed in Schneider et al., 
2013; Zwergel, Stazi, Valente and Mai, 2016).        
 
Figure 2.5 Epigenetic modifications of histone tails by histone acetylation through the 
balance of histone acetyltransferase (HAT) and histone deacetylase 
(HDAC) regulation and family distinguishes (Schneider et al., 2013). 
 
2.8  Histone deacetylase inhibitors (HDACi) 
HDACi possesses usually the following well-known components: a cap group 
(CAP) allow interacting with the catalytic tunnel border of the enzyme, a polar 
connection unit (CU) connecting to a hydrophobic spacer (HS) enabling the inhibitor 
to lie into the aforementioned tunnel, and a Zn-binding group (ZBG) able to complex 
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the Zn
2+
 at the bottom of the enzyme cavity. To date numerous different CAP, CU, HS 
and ZBG combinations as HDACi have been either isolated from natural sources or 
synthesized displaying varying target specificity, pharmacokinetic properties and 
activity in laboratory and clinical settings (reviewed in Zwergel, Stazi, Valente and 
Mai, 2016). 
Inhibition of HDACs by HDAC inhibitors (HDACi) were used widely in anti-
cancer treatments through several structurally distinct HDAC inhibited, most of which 
divided into four major chemical classes (Table 2.2) (reviewed in Smith and 
Workman, 2009). More recently, clinical studies also using HDACi have been 
extended to a range of non-oncologic diseases, such as neurological disorders, 
inflammatory processes and viral infections (reviewed in Delcuve, Khan and Davie, 
2012; Zwergel, Stazi, Valente and Mai, 2016). 
Table 2.2 HDACi classification and specificity (reviewed in Smith and Workman, 2009). 
Class of inhibitors HDACs inhibited HDACi names Stage of clinical 
development 
I. Hydroxamates Class I, II and IV  SAHA (Vorinostat®) 
PXD101 (Belinostat®) 
Tricostatin A (TSA) 
FDA approved for CTCL 
Phrase I 
None 
2. SCFAs 
 
Class I, IIa: 4, 5, 9 Sodium butyrate (NaB) 
Sodium phenylbutyrate 
Valproic acid (VPA) 
Phrase II 
Phrase II 
Phrase II 
3. Benzamides  
 
Class I 
Class I, IV 
MS-275 
MGCD-0103 
Phrase II 
Phrase II 
4. Cyclic tetrapeptides 
  
Class I Depsipeptide (FK228) 
Apicidin 
Phrase II 
Preclinical 
ABBREVIATION: CTCL: Cutaneous T cell lymphoma: FDA: Food and Drug Administration, SCFAs: short-chain fatty acids, 
SAHA: Suberoylanilide hydroximc acid. 
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2.8.1  HDACi on hepatogenic differentiation of hMSCs 
 Presently, HDACi commonly have been used on hMSC differentiation 
toward hepatoendodermal lineage, such as TSA (hydroxamates) and VPA 
(carboxylates) to overcome stem cell fate determination (Snykers et al., 2007; Banas et 
al., 2007; Zheng et al., 2008; Dong et al., 2013; An et al., 2014). 
 The successfully differentiated hMSCs into hepatocyte-like cells by 
exposing with HDACi for 27 days was reported by Snykers and coworkers (2006). 
They compared hepatogenic differentiation medium cocktail (FGF-4, HGF, ITS and 
dexamethasone) and sequential (FGF-4, followed by HGF, and followed by a 
combination of TSA, HGF, ITS and dexamethasone) with or without TSA 
supplementation from day 6 onward. These results found that the differentiated cells 
of hepatogenic differentiation medium sequential with TSA supplementation could 
express highest hepatic phenotypes and functional maturation of hBM-MSCs when 
compared with other groups. Besides, these hBM-MSCs differentiation toward 
hepatocyte-like cells could regulate through histone acetylation on histone H4 by 
TSA-induced HDAC inhibition. Nevertheless, Seo and collaborates (2005) 
performed firstly the successful of differentiated hADSCs into hepatocyte-like cells 
by exposing with 0.1% dimethyl sulfoxide (DMSO) in hepatogenic medium (HGF 
and OSM) from day 10 onward, but the mechanism underlying the hepatic 
transdifferentiation-inducing effects of DMSO has not yet been fully elucidated, 
though histone hyperacetylation-inducing effects have been suggested for the action 
of DMSO (Sarg et al. 2004). hAF-MSCs could also induce to hepatocyte-like cells by 
exposing TSA with hepatogenic differentiation medium sequential at step-2 (FGF-4 
and HGF, and followed by dexamethasone, ITS, and HGF)  (Zheng et al., 2008). 
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Nevertheless, hWJ-MSCs could also differentiate into hepatocyte-like cells by 
exposing TSA at final step of 4-step hepatogenic differentiation medium (FGF-4, 
followed by ITS and HGF, followed by dexamethasone, ITS, glucagon and OSM, 
and followed by dexamethasone, ITS, glucagon and OSM+TSA or DMSO) for 21 
days (Yoon et al., 2010). More recently, hBM-MSCs could differentiated into 
functional mature hepatocyte-like cells by exposing VPA-induced HDAC inhibition 
for 72 h pre-treatment through regulation of histone acetylation on histones H3 and 
H4  before culturing in hepatogenic differentiation sequential (FGF-4, followed by 
HGF, and followed by HGF, OSM and dexamethasone) for 21 days (Dong et al., 
2013). Another report, emphasize that VPA-induced HDAC inhibition could also 
enhance hWJ-MSCs differentiation into hepatocyte-like cells by exposing VPA-
induced HDAC inhibition for 6 h pretreatment through mitogen-activated protein 
kinases/extracellular signal-regulated kinase (MAPK/ERK) and phosphatidylinositol 
3-kinase/Protein Kinase B (PI3K/AKT) signaling pathways of endoderm 
specification before culturing in hepatogenic differentiation cocktail (HGF, OSM and 
dexamethasone) for 15 days (An et al., 2014). However, no study MSC 
differentiation into functional mature hepatocyte-like cells by exposing NaB, so this 
study we would like to investigate effect of NaB on hepatogenic differentiation of 
hWJ-MSCs. 
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2.9 Sodium butyrate (NaB) 
 NaB is the short-chain fatty acid butyric acid in sodium salt formed (Ghosh et 
al. 2012). Normally, butyrate is a 4-carbon fatty acid that produced by anaerobic 
bacterial fermentation of dietary fibers through hydrolysis of ethylbutyrate, and is 
known to play a key role in the homeostasis of the gastrointestinal tract (Liu et al., 
2014).  
The first study of NaB was reported by Pace and coworkers (1967) by treating 
on mammalian cell cultures in vitro, the result showed that it affected morphology, 
growth rate and gene expression. But at higher concentrations of NaB (10 mM and 
above) were toxic to the cells. Nowadays, NaB not only used as antitumor agents, but 
also for non-oncologic uses for years and has been shown to have HDACi activity, 
such as anti-inflammatory agents, cystic fibrosis treatment and application of 
neurodegenerative disorders trials (reviewed in Canani, Costanzo and Leone, 2012). 
Therefore, NaB has been regarded as the epigenetic effects with potential clinical 
applications in further human medicine. 
Recently, NaB has been found to play an important role in stem cell 
differentiation through HDACi activity at millimolar (mM) range of therapeutic 
concentrations (Chen et al., 2007; Vrba, Trtkova and Ulrichova, 2011; Shah et al., 
2013). Besides, NaB can also specifically induce the generation of hepatic progenitor 
cells from ESCs (Zhang et al., 2011), osteoblast and inhibit adipogenic differentiation 
(Rahman et al., 2003; Chen et al., 2007) and smooth muscle cell differentiations from 
MSCs (Liu et al., 2014), suggesting that NaB might be an effective regulator to 
promote MSC differentiation into certain terminal cell types.  
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Previous study, many reports of hepatic differentiation of ESCs found that NaB 
could promote ESCs differentiation toward hepatocyte-like cells (Rambhatla et al., 
2003; Sharma et al., 2006; Zhou et al., 2007; Hay et al., 2008; Ren et al., 2010; Zhou 
et al., 2010). However, no study the effect of epigenetic modifiers of HDACi NaB on 
hepatogenic differentiation of MSCs. Therefore, these statements will be increased the 
effect of HDACi NaB on hepatogenic differentiation through epigenetic modification 
through histone acetylation. 
CHAPTER III 
MATERIALS AND METHODS  
 
3.1  Chemicals and Reagents 
All chemicals and reagents were purchased from Sigma-Aldrich Corporation 
(St. Louis, MO, USA), unless otherwise indicated.  
 
3.2  Human hepatocarcinoma (hHep G2) and NIH3T3 cell culture  
hHep G2 and NIH3T3 cell lines were cultured in Dulbecco’s Modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Life 
Technologies Inc. Gibco-BRL Division, Grand Island, NY, USA) and 100 μg/ml 
streptomycin and 100 U/ml penicillin at 37ºC in a humidified atmosphere with 5% 
CO2. hHepG2 and NIH3T3 cells were used as a positive control in the experiments. 
 
3.3  Isolation and culture of hWJ-MSCs 
 A Human umbilical cord was collected and preserved aseptically after full-term 
delivery from Suranaree University of Technology Hospital, Nakhon Ratchasima with 
patient’s consent. Isolation and cultivation of hWJ-MSCs was performed by tissue 
explant procedure as previously described (Petsa et al., 2009). Briefly, Wharton’s Jelly 
was cut into small pieces of about 3 3 mm2 after removing vessels and other parts of
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the tissue. The tissues were plated in a six-well plate (SPL Life Sciences, Gyeonggi-do, 
Korea) and cultured in standard growth medium composed of Alpha-Minimum 
Essential medium (α-MEM) supplemented with 10% FBS and 100 μg/ml streptomycin 
and 100 U/ml penicillin and incubated at 37oC with saturated humidity containing 5% 
CO2. Culture cells were then incubated at 37ºC in a humidified atmosphere of 5% CO2 
in air for 7-10 days. Medium was replaced every 2 days and, when visible fibroblast-
like cells were observed, the remained pieces of tissue explants were removed. The 
cells were expanded further until passage 3 and the cells were either directly used for 
experiments or cryopreserved with 10% dimethyl sulfoxide (DMSO, Calbiochem, San 
Diego, CA, USA) and stored in liquid nitrogen. 
 
3.4  Treatment of NaB 
 Various concentrations of NaB 0, 1, 2.5 and 5 mM were added in serum-free 
medium, Iscove’s Modified Dulbecco’s medium (IMDM) supplemented with 20 ng/ml 
EGF (Peprotech, Rocky Hill, NJ, USA), 10 ng/ml bFGF (Peprotech) and 100 μg/ml 
streptomycin and 100 U/ml penicillin of hWJ-MSCs pre-treatment before hepatogenic 
differentiation, for 72 h at 37ºC in a humidified atmosphere of 5% CO2 in air. The pre-
treated cells with (the PTM + 1, 2.5 and 5 mM NaB groups) and without NaB (the 
PTM group) were checked for the endodermal-related gene expressions by qPCR and 
immunocytochemistry for SOX17 expression. The HDAC1 expression was also 
checked by immunofluorescence, qPCR and Western blot analyses.  
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3.5  Immunophenotyping 
hWJ-MSCs at passage 5 were cultured on 4-well tissue culture dishes (Nunc, 
Roskilde, Denmark) until reaching 80% confluence. Cells were fixed with 4% 
paraformaldehyde (PFA) for 30 min. Nonspecific binding was blocked with 10% 
normal goat serum. Primary antibodies against CD34 (BD biosciences, San Jose, CA, 
USA), CD73 (Millipore, Massachusetts, USA), CD90 (Santa Cruz Biotechnology, 
Dallas, TX, USA), and CD105 (Santa Cruz Biotechnology) were added and incubated 
at 4°C overnight. Cells were the incubated with secondary antibodies, Alexa fluor® 
488 goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) or Alexa fluor® 488 goat 
anti-rabbit IgG (Invitrogen). Nuclei were stained with 4, 6-diamino-2-phenylindole 
(DAPI; Millipore) and the stains were observed under a fluorescence microscope 
(Nikon Eclipse Ti-S, Japan). 
 
3.6 Multipotency assays 
hWJ-MSCs were cultured at the final density of approximately 2  104 
cells/cm2 on 6-well culture plates coated with 0.1% gelatin.  
hWJ-MSCs were induced to osteogenic differentiation by culture in the culture 
medium with reduced FBS to 5% and supplemented with 100 nM dexamethasone, 0.2 
mM L-ascorbate-2-phosphate, and 10 mM β-glycerophosphate. The medium was 
subsequently replaced every 2 days for 3 weeks. Calcium deposits from the cells were 
then visualized by Alizarin Red staining.  
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To induce adipogenic differentiation, hWJ-MSCs were cultured in the culture 
medium with reduced FBS to 5% and supplemented with 10 μg/mL insulin, 100 μM 
indomethacin, 1 μM dexamethasone, 0.5 mM isobutylmethylxanthine (IBMX). IBMX 
was removed from the medium after 1 week of culture. The medium was subsequently 
replaced every 2 days for 3 weeks. Cells were then stained with Oil Red O to observe 
cells containing oil droplets. 
To induce chondrogenic differentiation, hWJ-MSCs were cultured in a 
completed chondrogenic medium consisting of culture medium with reduced FBS to 
2% and supplemented with 1% Insulin-Transferrin-Selenium-Ethanolamine (ITS-X, 
Invitrogen), 50 μg/mL ascorbate-2-posphate, 40 μg/mL L-proline, 100 μg/mL sodium 
pyruvate, 100 nM dexamethasone, and 10 ng/mL of TGF-β3 (Prospec, East 
Brunswick, NJ, USA). The medium was replaced every 2 days for 3 weeks. 
Glycosaminoglycan production was assessed by Alcian blue staining.  
 
3.7  Hepatogenic differentiation 
Approximately 1.5103 cells of hWJ-MSCs were plated on 4-well plates for 
immunophenotypic examination and 1.5×105 cells were plated on 35 mm diameter 
dish (Corning, Acton, Massachusetts, USA) and 6-well plates for qPCR, glycogen 
storage and urea production assays, respectively. The plates were coated with 0.1% 
gelatin, and cultured in standard growth medium until reaching about 80-85% 
confluence. Hepatogenic differentiation was performed as described (Campard et al., 
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2008) with some modifications. Briefly, cells were cultured in IMDM without serum 
and supplemented with 10 ng/ml bFGF, 20 ng/ml EGF, 100 μg/ml streptomycin and 
100 U/ml penicillin and combined with and without the optimized concentrations of 
NaB for 72 h (in the pre-treatment step) obtained from Treatment of NaB mentioned 
above. Then, cells were induced to become hepatic lineages by 2-step differentiation 
protocol. Step 1 (in the differentiation step) consisted of IMDM without serum 
supplemented with 10 ng/ml bFGF, 40 ng/ml hepatocyte growth factor (HGF; 
Peprotech)  and 5 mM nicotinamide for 7 days. Step 2 (in the maturation step) 
consisted of IMDM without serum supplemented with 10 ng/ml oncostatin M (OSM), 
110-8 M dexamethasone and 1% ITS-X for 14 days (Fig. 3.1). In all steps, media were 
changed twice weekly. 
 
 
Figure 3.1 Schematic diagram of hepatogenic differentiation protocol of hWJ-MSCs. 
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3.8  Cytotoxicity test 
One thousand hWJ-MSCs were re-plated and cultured in 96-well culture plates 
(SPL life sciences) in the culture medium for 6 h to allow attachment. The NaB 
cytotoxicity was assessed by adding NaB to the culture medium at the concentrations 
of 0, 1, 2.5 and 5 mM, respectively. All cultures were maintained at 37ºC for 72 h in a 
humidified atmosphere of 5% CO2 in air. The effects of NaB on cell viability were 
quantified by the MTT assay (Liu et al., 2014). Briefly, culture medium was replaced 
by 5 mg/mL MTT solution (Invitrogen) in culture medium and cells were incubated 
for 2 h. DMSO was then added and incubated at 37oC for 10 min. The absorbance was 
measured at 540 nm (Microplate reader Sunrise, TECAN, Austria). 
 
3.9  Gene expression analysis  
After 3, 10, 17 and 24 days of differentiation, total RNA was isolated from the 
cells by total RNA extraction kit (RBC Real Genomics, RBC Bioscience, Taipei, 
Taiwan) according to the manufacturer’s instructions. Then, the RNAs were reverse-
transcribed in the presence of oligo-dT primer for complementary DNA (cDNA) 
synthesis by iScript™ Reverse Transcription Supermix for qPCR (BioRad, Hercules, 
CA, USA). The expression of genes in Table 3.1 was assessed by using Light Cycler® 
480 (Roche Diagnostics, Basel, Switzerland) and KAPA SYBR-Green PCR Master 
mix (Applied Biosystems, Carlsbad, CA, USA). The primers used are shown in Table 
3.1. Melting curve analysis was also checked to determine the specificity of the 
primers. Gene expression was normalized to the reference gene GAPDH and 
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calculated as relative expression compared to control cells. The qPCR were performed 
in triplicates. 
 
Table 3.1 Primers used for qPCR analysis. 
Genes Primer Sequence Annealing 
Temp. (oC) 
Size 
(bp) 
References 
 
SOX17 
 
CXCR4 
 
GATA6 
 
AFP 
 
HNF3β 
 
CK18 
 
ALB 
 
HDAC1 
 
GAPDH 
 
Forward 5’-GGCGCAGCAGAATCCAGA-3’  
Reverse 5’- CCACGACTTGCCCAGCAT-3’ 
Forward 5’- ACTACACCGAGGAAATGGGCT-3’  
Reverse 5’- CCCACAATGCCAGTTAAGAAGA-3’ 
Forward 5’-CCATGACTCCAACTTCCACC-3’   
Reverse 5’-ACGGAGGACGTGACTTCGGC-3’ 
Forward 5’-CTTTGGGCTGCTCGCTATGA-3’  
Reverse 5’-GCATGTTGATTTAACAAGCTGCT-3’ 
Forward 5’- CCTACTCGTACATCTCGCTCATC-3’  
Reverse 5’-CGCTCAGCGTCAGCATCTT-3’ 
Forward 5’-TCGCAAATACTGTGGACAATGC-3’  
Reverse 5’-GCAGTCGTGTGATATTGGTGT-3’ 
Forward 5’-GCACAGAATCCTTGGTGAACAG-3’  
Reverse 5’-ATGGAAGGTGAATGTTTCAGCA-3’ 
Forward 5’-CCAAGTACCACAGTGATGACTACATT-3’  
Reverse 5’- AGAACTCAAACAGGCCATCAAA-3’ 
Forward 5’-TGCACCACCAACTGCTTAGC-3’  
Reverse 5’-GGCATGGACTGTGGTCATGAG-3’ 
 
65 
 
60 
 
62 
 
60 
 
65 
 
60 
 
65 
 
65 
 
60 
 
61 
 
133 
 
214 
 
131 
 
69 
 
171 
 
101 
 
135 
 
87 
 
[36] 
 
This study 
(NM_003467.2) 
[37] 
 
This study 
(NM_001134) 
[33] 
 
This study 
(NM_199187.1) 
 [38] 
 
This study 
(NM_004964.2) 
[38] 
         
3.10 Immunofluorescence staining 
The cells at day 3, 10, 17 and 24 were fixed with 4% PFA for 30 min, then 
they were blocked and permeabilized for 2 h at 37°C with 2% bovine serum albumin 
(BSA), 5% normal goat serum, 3 mM sodium azide and 0.2% triton-X100. The cells 
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were incubated at 4 
o
C overnight with primary antibodies as follow: mouse anti-human 
α-fetoprotein (AFP) (1:100), mouse anti-human cytokeratin18 (CK18) (1:100; Santa 
Cruz Biotechnology), rabbit anti-human hepatocyte nuclear factor 3β (HNF3β) (1:100; 
Santa Cruz Biotechnology) and rabbit anti-human albumin (ALB) (1:200; Abcam, 
Cambridge, UK). Then, samples were incubated for 2 h with the respective secondary 
antibodies. Samples were stained with DAPI and observed under a fluorescence 
microscope. Besides, HDAC1 and SOX17 protein expression for 72 h was also 
investigated by immunofluorescence staining with rabbit anti-human HDAC1 (1:200; 
Millipore) and mouse anti-human SOX17 (1:100; Abcam) primary antibodies.  
 
3.11  Western blot analysis 
Total protein was extracted from the samples for 72 h post-induction by lysis 
buffer containing 10% sodium dodecyl sulfate (SDS), 0.1 M dithiothreitol (DTT, 
Invitrogen), 1% glycerol, 1.2% urea, and 1 M Tris-HCl pH 7.4 and complete protease 
inhibitor. The total protein concentration was determined by Bradford assay (Bradford, 
1976). Twenty micrograms of total protein were separated on 10% SDS-PAGE, 
followed by electro-transfer to nitrocellulose membrane (BioRad). The membranes 
were exposed to blocking buffer (5% skim milk in PBS with 0.1% Tween-20 (PBS-T)) 
and then incubated with either anti-human HDAC1 (dilution 1:500, Millipore) or anti-
human β-actin (dilution 1:1,000, Millipore). Membranes were incubated with (goat 
anti-rabbit or -mouse) secondary antibody conjugated to alkaline phosphatase (dilution 
1:20,000) and were then developed by using 5-Bromo-4-chloro-3-indolyl 
phosphate/Nitro blue tetrazolium (SIGMA FAST™ BCIP/NBT). 
  
38 
 
3.12  Periodic acid-Schiff staining 
 The cells were cultured until day 3, 10, 17, and 24 were fixed with 4% PFA 
and oxidized in 1% periodic acid in PBS- for 30 min, and washed three times in 
deionized (DI) water. Then, they were incubated in Schiff’s reagent for 15 min. After 
that they were washed with DI water for 5 min, the cells were then visualized under an 
inverted microscope. 
 
3.13  Urea production 
The cells from each experimental group, hWJ-MSCs, the pre-treatment stage 
(d3), the early stage (d10), the mid-stage (d17) and the late stage (d24) of the hWJ-
MSCs differentiation with and without NaB pre-treatment and hHep G2, as positive 
cells, were incubated with IMDM containing 5 mM NH4Cl for 24 h and the 
supernatants were colorimetrically measured according to the manufacturer’s 
instructions (Quantichrom™ Urea assay kit, Bioassay Systems, CA, USA). Fresh 
culture media supplemented with 5 mM NH4Cl was used as a negative control. 
Samples from separate culture were analyzed in triplicate for each group. 
 
3.14 Statistical analysis 
 Statistical analysis was performed using the SPSS version 16.0 (SPSS, Inc., 
USA), and data were expressed as mean S.D. Differences between the values were 
determined using the independent sample by using one-way analysis of variance 
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(ANOVA) with Turkey’s HSD Post Hoc Test to compare between two groups. The 
data were analyzed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). 
A value of P 0.05 was considered to be significant, whereas P 0.001 was highly 
significant difference. 
 
CHAPTER IV 
RESULTS 
 
4.1  Isolation and characterization of hWJ-MSCs 
 hWJ-MSCs were obtained from the isolation of a tissue explant procedure as 
previously described (Petsa et al., 2009). The migrated cells from the tissue showed 
fibroblast-like shaped after cultured (Fig. 4.1A) and become 80% confluences in 7 
days (Fig. 4.1B). The cells were harvested and expanded for further use. 
 
Figure 4.1 Morphology of hWJ-MSCs with typical fibroblast-like morphology. (A) A 
phase contrast images of hWJ-MSCs expanded form Wharton’s Jelly 
tissue and (B) hWJ-MSCs at 80% confluences. Scale bar: 100 (A) and 50 
(B) μm. 
 The MSC signatures from umbilical cord Wharton’s Jelly tissue were 
characterized at the 4
th
 passage with immunophenotype and multipotency assays. Tri-
mesodermal lineages differentiation potentials in vitro of hWJ-MSCs were examined 
after 21 days of induction with Alizarin Red, Alcian Blue and Oil Red O staining for 
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osteogenic, chondrogenic and adipogenic characterizations, respectively. The 
differentiated cells positively formed calcium mineralization of osteoblast (Fig 4.2A), 
proteoglycan matrix of chondroblast (Fig. 4.2B) and intracytoplasmic lipid droplets of 
adipocyte (Fig. 4.2C). Immunocytochemical analysis showed that hWJ-MSCs 
positively expressed MSC markers CD73, CD90 and CD105, while the expression of 
expressed CD34, hematopoietic marker, was not detected (Fig. 4.2D-G). These data 
demonstrated that the hWJ-MSCs have typical MSC characteristics. 
 
 
Figure 4.2 Characterization of hWJ-MSCs. (A-C) Multilineage differentiation 
potential of hWJ-MSCs after 21 days, evaluated by (A) Alizarin Red 
(osteogenic), (B) Alcian Blue (chondrogenic) and (C) Oil Red O 
(adipogenic) staining. Scale bar: 100 (A & B) and 10 (C) μm. (D-G) 
Representative images of immunophenotype of hWJ-MSCs (D) CD73, (E) 
CD90, (F) CD105 and (G) CD34. Scale bar: 50 μm.   
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4.2  Effect of NaB of hWJ-MSCs viability  
 To examine the cytotoxicity of NaB, hWJ-MSCs were cultured in serum-free 
medium supplemented with the various concentrations of NaB (0, 1, 2.5 and 5 mM) 
for 72 h and then they quantified by using MTT assay. The 1 mM NaB 
supplementation showed significantly higher cell viability (98.39±0.98%) when 
compared to the 2.5 and 5 mM NaB supplementation groups (81.77±0.53% and 
79.01±0.82%), respectively (Fig. 4.3).  These data demonstrated that 1 mM NaB can 
be used for hepatogenic differentiation in pre-treatment step.  
 
Figure 4.3  Effect of NaB on cytotoxicity of hWJ-MSCs. hWJ-MSCs were cultured 
with 0-5 mM NaB for 72 h in 96-well plate. Then, the viability was 
determined by MTT assay. Data were shown as means ± SD. *p < 0.05.  
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4.3  Combination of NaB with EGF and bFGF pre-treatment of 
hWJ-MSCs differentiation 
To investigate whether dose-dependent manner of NaB pre-treatment was 
probably done through HDAC1 inhibition, the endodermal-related gene expressions 
were observed. hWJ-MSCs pre-treatment with various concentrations of NaB (0, 1, 
2.5 and 5 mM) and supplemented with EGF and bFGF in the pre-treatment medium 
(PTM) for 72 h before hepatogenic differentiation where check for the endodermal-
related gene expression. The mRNA levels of endodermal-related genes, CXCR4, 
SOX17 and GATA6 were quantified by qPCR. As shown in Fig. 4.4A-C, hWJ-MSCs 
cultured in the PTM + 1 mM NaB group gave rise to the highest expressions fold 
change of CXCR4, SOX17 and GATA6 which were statistically significant different 
when compared to other groups. Similar to the qPCR data, SOX17-positive cells were 
detected in the PTM + 1 mM NaB group (Fig. 4.4F) greater than the control (hWJ-
MSCs) (Fig. 4.4D) and the PTM group (Fig. 4.4E). However, in the PTM + 2.5 and 5 
mM NaB groups (Fig. 4.4G-H), SOX17 expressed cells were not detected. All of the 
result demonstrated that the PTM + 1 mM NaB group up-regulated the endoderm-
related genes and SOX17 protein expressions. Accordingly, the PTM + 1 mM NaB 
group inhibited HDAC1 protein expression shown by immunofluorescent and Westren 
blot analyses (Fig. 4.5A-E and Fig. 4.5F), respectively. However, the mRNA levels of 
HDAC1expression of the PTM + 1 mM NaB group were partially inhibited but with 
not significantly difference when compared to the PTM group (Fig. 4.5G). These 
results demonstrated that the hWJ-MSCs can differentiate into endodermal lineage 
through HDAC1 inhibition in the PTM + 1 mM NaB pre-treatment. Besides, this 
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result also confirmed that the PTM + 1 mM NaB pre-treatment can be used for 
hepatogenic differentiation of hWJ-MSCs. 
 
 
Figure 4.4  Effect of NaB on endodermal differentiation of hWJ-MSCs after NaB 
treatment. (A-C) qPCR analysis of embryonic endodermal gene 
expressions for (A) CXCR4, (B) SOX17 and (C) GATA6 after 72 h of pre-
treatment. Gene expressions were normalized to corresponding GAPDH 
and calculated by relative fold expression compared to control cells (hWJ-
MSCs). The experiments were performed in triplicates. Data were shown 
as mean ± SD, **p < 0.001. (D-H) Representative indirect 
immunofluorescent staining for SOX17 after NaB (0, 1, 2.5 and 5 mM) 
pre-treatments combined with EGF and bFGF for 72 h. Scale bar: 10 μm. 
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Figure 4.5 Effect of NaB on histone deacetylase 1 (HDAC1) inhibition. (A-E) 
Representative indirect immunofluoresence staining for HDAC1 after 
various concentrations of NaB (0, 1, 2.5 and 5 mM) pre-treatment 
combined with EGF and bFGF and control group for 72 h. Scale bar: 10 
μm.  (F) Western blot analysis for the HDAC1 protein levels after pre-
treatment for 72 h and β-actin was used as an internal control. (G) qPCR 
analysis for the HDAC1 gene expressions after 72 h of pre-treatment. Gene 
expressions were normalized to corresponding GAPDH and calculated by 
relative fold expression compared to control cells (hWJ-MSCs). NIH3T3 
cells were used as positive control. The experiments were done triplicates. 
Data were shown as mean ± SD, *p < 0.05. 
 
 
 
  
46 
 
4.4  Hepatogenic differentiation and characterizations  
We next examined the hWJ-MSCs differentiation into hepatocyte-like cells by 
the optimized NaB concentration of 1 mM pre-treatment combined with EGF and 
bFGF for 72 h before differentiated to hepatic lineage with 2-step differentiation 
protocol of Campard and colleagues with some modification. The morphological 
changes were determined on day 3, 10, 17 and 24 followed the differentiation. Upon 
differentiation, we observed morphological changed from fibroblast-like cells of hWJ-
MSCs into round or polygonal cells of hepatocyte features (S1 Fig., Appendix A). At 
day 3, the fibroblast-like morphology of hWJ-MSCs did not change much in both 
groups of the differentiated hWJ-MSCs with and without NaB pre-treatment (Fig. 
4.6A-B).  On day 10 of differentiation, the cells shape changed into more spindles like 
(Fig. 4.6C-D) and continuously changed into epithelial round on day 17 (Fig. 4.6E-F) 
and and polygonal cells on day 24 (Fig. 4.6G-H), in both differentiated hWJ-MSCs 
with and without NaB pre-treatment groups. 
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Figure 4.6  Hepatic-like cell features of the differentiated hWJ-MSCs. Morphology of 
the differentiated hepatocyte-like cells from hWJ-MSCs with and without 
NaB pre-treatment in EGF and bFGF supplementation at d3 (A-B), 10 (C-
D), 17 (E-F) and 24 (G-H) were observed under a phrase contrast 
microscope following the differentiation period. Scale bar: 50 μm. 
 
The hepatic markers, AFP, HNF3β, CK18 and ALB were examined by qPCR 
and immunofluorescent analyses on day 3, 10, 17 and 24 following differentiation. 
The qPCR data demonstrated that the expression of AFP, HNF3β, CK18 and ALB 
increased with time in both differentiated hWJ-MSCs with and without NaB pre-
treatment groups during hepatogenic differentiation with different levels (Fig 4.7). 
During the early stages (within 10 days) of differentiation, much higher transcript 
levels of AFP and HNF3β (Fig. 4.7A-B), could be detected in the differentiated hWJ-
MSCs with NaB pre-treatment group than the differentiated hWJ-MSCs without NaB 
pre-treatment and the control groups and gradually decreased on day 17 and 24. 
However, expression of HNF3β transcripts of the differentiated hWJ-MSCs without 
NaB pre-treatment group was higher on day 17 and gradually decreased on day 24. 
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But the AFP-positive and HNF3β-positive cells were detected in the differentiated 
hWJ-MSCs with NaB pre-treatment group greater than the differentiated hWJ-MSCs 
without NaB pre-treatment group at the late stages of differentiation (Fig. 4.8B-C and 
E-F). At day 3, 10 and 17 of the differentiation the AFP-positive (S2 Fig., Appendix 
A) and HNF3β-positive (S3 Fig., Appendix A) cells were gradually detected on day 3 
and stronger on day 10 and 17, respectively.  Therefore, this result indicated that 
hepatogenic differentiation in NaB pre-treatment group occurred earlier than in the 
control (hWJ-MSCs) and NaB non-pre-treatment groups. According to the earlier 
hepatogenic differentiation markers of protein expressions, day 24 of the 
differentiation the strongest expression of CK18 and ALB were also detected in both 
NaB pre-treatment (Fig. 4.8H and K) and NaB non-pre-treatment (Fig. 4.8I and L) 
groups, respectively. On day 3, 10 and 17 of the differentiation, CK18 (S4 Fig., 
Appendix A) and ALB (S5 Fig., Appendix A) were also expressed but less on day 3 
and 10 and stronger on day 17. The expression of CK18 (Fig. 4.7C) and ALB (Fig. 
4.7D) mRNA from the qPCR data indicated that the hWJ-MSCs differentiated into 
hepatiocyte-like cells. During the early stage (within 10 days) of differentiation, the 
expression of mRNA levels of CK18 and ALB, were detected higher in the 
differentiated hWJ-MSCs with NaB pre-treatment group than the differentiated hWJ-
MSCs without NaB pre-treatment and the control groups in different levels. On day 17 
of differentiation, the differentiated hWJ-MSCs with NaB pre-treatment group much 
gradually increased in both CK18 and ALB mRNA expression and highest expression 
levels on day 24 of differentiateion, which were statiscally different when compared to 
the differentiated hWJ-MSCs without NaB pre-treatment and the control groups. 
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Therefore, these results demonstrated that hWJ-MSCs differentiated into hepatoblast-
like and hepatocyte-like cells after NaB pre-treatment in hepatogenic differentiation. 
 
 
Figure 4.7 Heptic-specific gene expressions of the differentiated hWJ-MSCs with and 
without NaB pre-treatment in EGF and bFGF supplementation. (A-D) 
qPCR analysis of hepatogenic gene expressions as AFP, HNF3β, CK18 
and ALB after differentiation. Gene expressions were normalized to 
GAPDH and calculated by relative fold expression compared to control 
cells (hWJ-MSCs). hHepG2 was used as positive control. The experiments 
were done in triplicates. Data were shown as mean SD, *p  0.05.  
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Figure 4.8 Hepatic-specific protein expressions of the differentiated hWJ-MSCs with 
and without NaB pre-treatment in EGF and bFGF supplementation by 
immunofluorescent analysis at day 24.  The differentiated hWJ-MSCs with 
and without NaB pre-treatment in EGF and bFGF supplementation were 
stained with a specific antibody for (A-C) AFP, (D-F) HNF3β, (G-I) CK18 
and (J-L) ALB, respectively. Scale bar: 50 (A-C & G-L) and 10 (D-F) 
μm. 
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Biochemical functions of mature hepatocytes were assessed by the observation 
of cytoplasmic glycogen granules storage with Periodic acid-Schiff (PAS) staining and 
urea production assays at day 3, 10, 17 and 24 of differentiation. The results indicated 
that the undifferentiated hWJ-MSCs group did not show positive signal of PAS 
staining (Fig. 4.9A), but the differentiated hWJ-MSCs with NaB pre-treatment (Fig. 
4.9C) show strong signal of PAS staining when compare to the differentiated hWJ-
MSCs without NaB pre-treatment (Fig. 4.9B). This results corresponding to the 
protein expressions of hepatic markers at day 3, 10 and 17, that they increase the 
signal of PAS reaction on day 3 and 10, and stronger signal on day 17 in both groups 
of the differentiated hWJ-MSCs with and without NaB pre-treatment (S6 Fig., 
Appendix A). Urea secretion products from the metabolic function of ammonia 
detoxification were investigated at day 3, 10, 17 and 24 (Fig. 4.9D). In both groups of 
the differentiated hWJ-MSCs with and without NaB pre-treatment could be slightly 
detected urea at day 3 and 10 significantly difference when compared to control group, 
but no difference when compare between groups. On day 17 and 24 of differentiation, 
in both groups of the differentiated hWJ-MSCs with and without NaB pre-treatment 
gradually increased with significantly difference (∆p<0.05), and when compared to 
the control group, they were also difference (*p<0.05).  Therefore, this result indicated 
that hWJ-MSCs cultured in hepatogenic medium with 1 mM NaB pre-treatment for 72 
h can differentiated into matured hepatocyte-like cells with their functions greater than 
the cell grown in hepatogenic medium without NaB pre-treatment.  
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Figure 4.9 Functional evaluations of the differentiated hWJ-MSCs with and without 
NaB pre-treatment in EGF and bFGF supplementation. (A-C) Glycogen 
storage of the differentiated hWJ-MSCs with and without NaB pre-
treatment in EGF and bFGF supplementation at day 24, respectively, were 
characterized by PAS staining following the differentiation period. Scale 
bar: 100 μm. (D) The capacity of the differentiated hWJ-MSCs with and 
without NaB pre-treatment in EGF and bFGF supplementation to produce 
urea after differentiation for 24 days was determined by colorimetric 
following the differentiation period. hHepG2 was used as positive control. 
Data were shown as mean   SD,  ,*p  0.05. 
CHAPTER V 
DISCUSSION AND CONCLUSION 
 
Nowadays, transplantation of undifferentiated umbilical cord-MSCs (UC-
MSCs) has been applied in the degenerative diseases patients including liver diseases. 
Although, the transplantation can improve the liver function of the model of end-stage 
liver disease (MELD) symptoms, the survival rate is still low (Zhang and Wang, 
2013). Other cell types may be needed if one wants to practice cell-based therapy. 
Based on their advantages, hWJ-MSCs seem to possess beneficial effect on liver 
disease treatment. The hWJ-MSCs-derived hepatocyte-like cells might be viewed as 
an alternative promising resource.  
In this study, the early population of MSCs was obtained from human 
umbilical cord WJ tissue-by-tissue explants according to isolation procedure (Petsa et 
al., 2009) after removing umbilical blood vessels. Our data showed that hWJ-MSCs 
positively expressed MSC markers; CD73, CD90 and CD105, but did not expressed 
CD34-hematopoietic marker. They can also be differentiated into osteoblasts, 
chondrocytes and adipocytes of tri-mesodermal lineage differentiation potential in 
vitro. Therefore, these data indicated that the hWJ-MSCs used in this study could 
possess the hMSC characteristics of the International Society for Cellular Therapy 
(ISCT) criteria (Dominici et al., 2006).  
This study has improved the method for in vitro hWJ-MSCs differentiation
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into hepatocyte-like cells by using the pre-treatment of NaB combined with EGF and 
bFGF in the pre-treatment step of hepatogenic differentiation. Talѐns-Visconti and 
colleagues (2006) used EGF and bFGF pre-treatment for 48 h of MSCs differentiation 
toward hepatocyte-like cells in order to arrest cell proliferation. Besides, the 
specification of foregut-midgut organ-specific lineages of endoderm derived from 
ESC differentiation includes hepatocytes, was successfully obtained by bFGF at low 
concentration (Ameri et al., 2010).  To help the endodermal lineage specification, we 
changed the pre-treatment from 48 to 72 h for hepatogenic differentiation. Previously, 
another HDACi VPA pre-treatment prior to the hepatogenic differentiation of mBM-
MSCs (Chen et al., 2009) and hBM-MSCs (Dong et al., 2013) successfully obtained 
hepatocyte-like cells. Here, we the optimized NaB concentration (0-5 mM) in the pre-
treatment step to drive endodermal lineage specification. Normally, CXCR4 is used as 
endoderm marker specification in ESCs differentiation into endodermal lineage (King 
et al., 2008). Besides, SOX17 and GATA6 are also widely used as endoderm markers 
(An et al., 2014; Takayama et al., 2013). The SOX17 is a high-mobility-group box 
domain (HGM domain) transcription factor, essential for definitive endoderm 
formation (Wang et al., 2015). The transcription factor GATA6, zinc finger type that 
is the one type of GATA factors, important in mesendoderm specification; heart 
(mesoderm) and liver (endoderm) formation (reviewed in Gordillo, Evans and Gouon-
Evans, 2015). Surprisingly a greater effect than that of the conventional method was 
found. Our result showed that in the pre-treatment medium (PTM) + 1 mM NaB 
group, endodermal-related gene expressions, CXCR4, SOX17 and GATA6 were up-
regulated higher than in other groups. The SOX17-positive cells were also detected in 
the PTM + 1 mM NaB group greater than other groups.  
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The balance of HDACs and histone acetyltransferase (HATs) regulate histone 
acetylation of epigenetic modification. HDAC1 usually expressed to suppress gene 
expression (Liu et al., 2014). HDAC1 is known to be involved in endoderm 
organogenesis, including development of zebra fish (Noël et al., 2008).  It is possible 
that the NaB may control the cellular histone acetylation in chromatin remodeling 
during MSC differentiation into the specific cell types, similar to the osteoblasts and 
smooth muscle cell types (Liu et al., 2014; Chen et al., 2007; Lee et al., 2009). 
Previous studies showed that class I HDACs, such as hdac1 and hdac3 mutants in in 
vivo study of zebrafish, were inhibited by tricostatin A (TSA) (Noël et al., 2008) and 
valproic acid (VPA) (Farooq et al., 2008) which defected embryonic endoderm 
specification, including hepatogenesis. But, in vitro non-mutant study of VPA pre-
treatment in hepatogenic differentiation of hUC-MSCs obtained endodermal and 
hepatocyte-like cells (An et al., 2014). As inhibitor of HDACs, NaB, similar VPA 
group of HDACi, should enhance MSC differentiation to hepatocyte-like cells by 
inhibiting the enzymatic capacity of HDACs. Our data indicated that the PTM + 1 mM 
NaB group inhibited partially HDAC1 activity in gene and protein expressions, we 
proposed that the low concentration of NaB (1 mM) combined with EGF and bFGF in 
pre-treatment could drive endodermal-related gene up-regulation greater than the 
higher concentration (2.5 and 5 mM) and without NaB pre-treatment (0 mM) groups. 
Therefore, the partial inhibition of HDAC1 activity by NaB pre-treatement with EGF 
and bFGF maybe synergistically promote hWJ-MSCs differentiation toward 
endodermal lineage specification. However, the relationship between NaB and 
EGF/bFGF enhancement hWJ-MSCs differentiate into endodermal lineage via 
HDAC1 inhibition should be further investigated.  
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NaB is an HDAC inhibitor that has been proven to inhibit the proliferation of 
MSCs (Liu et al., 2014; Lee et al., 2009). The study of Liu and colleagues (2014) 
showed that 1 mM NaB treatment, arrest proliferation of hWJ-MSCs, however, in this 
study 1 mM NaB only slightly suppress MSC proliferation but not significantly 
different from the control, whereas other concentrations (2.5 and 5 mM) showed 
significantly suppression when compare to the control and the 1 mM NaB treatment 
groups. Therefore, the 1 mM NaB treatment was chosen for further study. To 
emphasize the previous evidences, NaB has been shown to promote hepatogenic 
differentiation from ESCs in pre-treatment (Hay et al., 2008; Cao et al., 2010) and 
differentiation (Rambhatla et al., 2003; Sharma et al., 2006; Zhou et al., 2007; 
Mizumoto et al., 2008; Ren et al., 2010; Yan et al., 2011) steps of the differentiation. 
Mizumoto and colleagues (2008) found that NaB alone cannot promote hepatogenic 
differentiation from ESCs in pre-treatment step similar to the previous study of 
MAPCs differentiation into hepatocyte-like cells (Schwartz et al., 2002). Nevertheless, 
the combination of NaB and activin A can promote hepatogenic differentiation greater 
than NaB or activin A alone (Mizumoto et al., 2008). This evidence was confirmed 
from the previous report of Cao and colleagues (2010) that NaB combined with bFGF 
and BMP4 consistently performed greater than growth factors, bFGF and BMP4 alone 
or bFGF and BMP4 combination.    
To induce MSCs toward hepatocyte-like cells, bFGF, HGF and nicotinamide 
play a key role in the early step of hepatic induction. The FGFs has an essential role in 
ventral foregut endoderm specification. HGF also plays a critical role in the 
development and regeneration of liver cells (Zhang, Lie and Wei, 2009) and 
nicotinamide are necessary for small hepatocyte colonies proliferation, its 
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differentiation from rat primary hepatocytes in in vitro (Chen and Zheng, 2011). At the 
differentiation and maturation stages, OSM, dexamethasone and ITS have been used 
on hepatogenic differentiation of MSCs (Zhao et al., 2009; Prasajak and 
Leeanansaksiri, 2013; Talѐns-Visconti et al., 2006; Ameri et al., 2010; Chen et al., 
2009). OSM, a member of interleukin-6 (IL-6) family, is involved in the main 
maturation fate of fetal hepatogenesis (Sidhu, Liu and Omiecinski, 2004). 
Dexamethasone and ITS are required for maintaining the expression of liver-enriched 
transcription factors (LETFs) and cell survival, respectively, which are essential for 
stimulating liver-specific genes transcription (Prasajak and Leeanasaksiri, 2013; 
Sidhu, Liu and Omiecinski, 2004). With the primitive origin of hWJ-MSCs, they are 
more immature MSCs than other adult MSCs sources (Zhao et al., 2009). Therefore, 
the lager amount of exogenous HGF (40-50 ng/ml) was used in order to trigger 
hepatogenic signal transduction system (Zhang, Lie and Wei, 2009; Zhao et al., 2009). 
Here, our result confirmed that after hWJ-MSCs treated with 20 ng/ml HGF in the 
first step of hepatogenic differentiation protocol for 21 days with pre-treatment step 
for 48 h, they cannot transdifferentiate into mature hepatocytes (data not shown). This 
data probably confirmed the previous study of Campard and colleagues (2008) that 
hWJ-MSCs can be induced to hepatocyte-like cells with 20 ng/ml HGF but with much 
longer time. Therefore, we changed the HGF concentration from 20 to 40 ng/ml, and 
showed that hWJ-MSCs were driven into hepatocyte-like cells greater than previous 
study.  
AFP, an early hepatic differentiation marker of fetal hepatocytes, has been 
investigated in hWJ-MSCs-derived hepatocyte-like cells (Zhang, Lie and Wei, 2009; 
Zhao et al., 2009, Prasajak and Leeanansaksiri, 2013). HNF3β or FOXA2 is a LETF 
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that has a crucial role in liver development and specified pre-hepatic fate through 
liver-specific gene during hepatogenic differentiation (Chen et al., 2009). Our data 
demonstrated that the differentiated hWJ-MSCs cells expressed HNF3β and AFP 
mRNA at an early stage of development. In the differentiated hWJ-MSCs cells with 
NaB pre-treatment their mRNA levels were much higher. However, for protein 
expression of AFP and HNF3β markers were detected strongest on day 24 of the 
differentiated hWJ-MSCs with NaB pre-treatment group. The hWJ-MSCs derived 
from more primitive origin seem to reserve the immature phenotype even though they 
have driven toward specific cell types (Prasajak and Leeanansaksiri, 2013). Compare 
to other HDACi chemicals, VPA pre-treatment on hepatogenic differentiation of BM-
MSCs, AFP and HNF3β gene and protein expression patterns similar to previous 
reports (Chen et al., 2009; Dong et al., 2013), but HNF3β gene expression were up-
regulated overtime.   Therefore, this result indicated that the differentiated hWJ-MSCs 
with NaB pre-treatment were driven toward hepatoblast-like cells greater than the 
differentiated hWJ-MSCs cells without NaB pre-treatment. 
In the mid to late stage of liver development, the differentiated hWJ-MSCs 
with and without NaB pre-treatment achieved characteristic of gene expressions and 
immunophenotypes of hepatic features by expressed CK18 and ALB. Because CK18 
and ALB have been reported to be mid-late and late stages of differentiation markers 
of liver organogenesis (Zhang, Lie and Wei, 2009). Compare to other HDACi group, 
VPA pre-treatment on hepatogenic differentiation of BM-MSCs (Chen et al., 2009; 
Dong et al., 2013) and UC-MSCs (An et al., 2014), ALB gene and protein expression 
patterns were similar to our data. Besides, the strongest PAS positive signals were 
detected in the differentiated hWJ-MSCs with NaB pre-treatment on day 24 of the late 
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stage of differentiation. However, the differentiated hWJ-MSCs with NaB pre-
treatment were not difference detected urea production at all stage of differentiation, 
they were significantly detected urea production difference from the control group on 
day 10, 17 and 24. Therefore, this result corresponds to previous study that they can be 
transdifferentiated into functional matured hepatocyte-like cells by storage glycogen 
(Campard et al., 2008; Zhang, Lie and Wei, 2009; Zhao et al., 2009; Prasajak and 
Leeanansaksiri, 2013) and urea production (Campard et al., 2008; Zhao et al., 2009; 
Prasajak and Leeanansaksiri, 2013) at the late stage of differentiation. According to 
previous study, glycogen storage from VPA pre-treatment (An et al., 2014; Chen et 
al., 2009; Dong et al., 2013) could give stronger PAS signal than VPA non-pre-
treatment. However, previous study found that VPA pre-treatment (Dong et al., 2013; 
An et al., 2014) in hepatogenic differentiation of MSCs could gradually increase urea 
production, especially, at the late stage of differentiation. Significantly difference 
between groups, our study found that between groups of the differentiated hWJ-MSCs 
with and without NaB pre-treatment were not different at the late stage of 
differentiation. Therefore, the increase time of culture might increase the urea 
production better.  
 Taken together, hWJ-MSCs can be differentiated into endodermal, 
hepatoblast-like and hepatocyte-like cells through HDAC1 inhibition by pre-treatment 
with NaB and combined with EGF and bFGF in the culture condition. Thus, hWJ-
MSCs have benefits over other adult MSCs and an attractive source for drug screening 
and cell-based therapy in liver diseases in the future. 
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APPENDIX A 
 
 
Supporting Information 
 
Figure S1  Hepatic-like cell features of the differentiated hWJ-MSCs. Morphology of 
the differentiated hepatocyte-like cells from hWJ-MSCs with and without 
NaB pre-treatment in EGF and bFGF supplementation at day 3, 10, 17 and 
24 and hHep G2 cell lines were observed under a phrase contrast 
microscope following the differentiation period. Scale bar: 10 (hHep G2, 
right-handed of bottom panel) and 50 μm.  
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Figure S2 Hepatic-specific protein expression of the differentiated hWJ-MSCs with 
and without NaB pre-treatment in EGF and bFGF supplementation by 
immunofluorescent analysis at day 3, 10, 17 and 24 of differentiation. The 
differentiated hWJ-MSCs with and without NaB pre-treatment in EGF and 
bFGF supplementation were stained with a specific antibody for AFP. 
Scale bar: 50 μm. 
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Figure S3  Hepatic-specific protein expression of the differentiated hWJ-MSCs with 
and without NaB pre-treatment in EGF and bFGF supplementation by 
immunofluorescent analysis at day 3, 10, 17 and 24 of differentiation. The 
differentiated hWJ-MSCs with and without NaB pre-treatment in EGF and 
bFGF supplementation were stained with a specific antibody for HNF3β. 
Scale bar: 10 μm. 
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Figure S4  Hepatic-specific protein expression of the differentiated hWJ-MSCs with 
and without NaB pre-treatment in EGF and bFGF supplementation by 
immunofluorescent analysis at day 3, 10, 17 and 24 of differentiation. The 
differentiated hWJ-MSCs with and without NaB pre-treatment in EGF and 
bFGF supplementation were stained with a specific antibody for CK18. 
Scale bar: 50 μm. 
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Figure S5  Hepatic-specific protein expression of the differentiated hWJ-MSCs with 
and without NaB pre-treatment in EGF and bFGF supplementation by 
immunofluorescent analysis at day 3, 10, 17 and 24 of differentiation. The 
differentiated hWJ-MSCs with and without NaB pre-treatment in EGF and 
bFGF supplementation were stained with a specific antibody for ALB. 
Scale bar: 50 μm. 
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Figure S6 Functional evaluation of the differentiated hWJ-MSCs with and without 
NaB pre-treatment in EGF and bFGF supplementation. Glycogen storage 
of the differentiated hWJ-MSCs with and without NaB pre-treatment in 
EGF and bFGF supplementation at day 3, 10, 17 and 24, respectively, 
were characterized by PAS staining following the differentiation period. 
Scale bar: 100 μm. 
 
 
 
 
 
 
APPENDIX B 
 
Table 1 Relative fold expression of endodermal-related genes compared to  
  control (hWJ-MSCs) at day 3 of differentiation (N=3). 
 
                            
                      Genes 
Conditions 
 
CXCR4 
 
SOX17 
 
GATA6 
 
HDAC1 
 
hWJ-MSCs (Control) 
 
 
1 0.23 
 
 
1 0.26 
 
 
1 0.25 
 
1 0.66 
 
Pre-treatment 
medium (PTM) 
 
 
1.68 0.66 
 
 
0.46 0.06 
 
 
0.65 0.16 
 
2.80 0.72 
 
PTM + 1 mM NaB 
 
 
12.79 0.72 
 
 
19.60 1.57 
 
 
4.87 0.40 
 
1.70 0.67 
 
PTM + 2.5 mM NaB 
 
 
1.14 0.15 
 
 
1.12 0.20 
 
 
2.70 0.69 
 
0.74 0.11 
 
PTM + 5 mM NaB 
 
 
0.82 0.11 
 
 
0.40 0.07 
 
 
0.74 0.24 
 
0.59 0.28 
 
NIH3T3 cells 
 
- 
 
- 
 
- 
 
9.73 0.44 
 
 
 
 
Table 2 Relative fold expression of hepatic genes compared to control at day 3, 10, 17 and 24 of differentiation (N=3). 
 
                         Genes 
 
Conditions 
 
AFP 
 
HNF3β 
 
Day 3 
 
Day 10 
 
Day 17 
 
Day 24 
 
Day 3 
 
Day 10 
 
Day 17 
 
Day 24 
 
hWJ-MSCs  
(negative control) 
 
 
1 0.16 
 
 
1 0.43 
 
 
1 0.48 
 
1 0.36 
 
 
1 0.26 
 
 
1 0.49 
 
 
1 0.90 
 
1 0.41 
 
Hepatogenic medium  
 
 
2.56 0.85 
 
 
15.66 3.18 
 
 
7.26 1.26 
 
0.50 0.31 
 
 
1.21 0.46 
 
 
5.50 0.32 
 
 
10.06 1.08 
 
3.27 0.05 
 
Hepatogenic medium 
+ NaB pre-treated 
 
 
6.50 1.25 
 
 
28.77 5.29 
 
 
11.69 1.87 
 
3.92 0.70 
 
 
7.33 0.54 
 
 
13.34 0.25 
 
 
2.87 0.90 
 
1.15 0.04 
 
hHep G2 cells  
(positive control) 
 
 
- 
 
 
- 
 
 
- 
 
193.21 10.16 
 
 
- 
 
 
- 
 
 
- 
 
61.99 19.28 
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Table 2 Relative fold expression of hepatic genes compared to control at day 3, 10, 17 and 24 of differentiation (N=3) (Continued). 
 
                         Genes 
 
Conditions 
 
CK18 
 
ALB 
 
Day 3 
 
Day 10 
 
Day 17 
 
Day 24 
 
Day 3 
 
Day 10 
 
Day 17 
 
Day 24 
 
hWJ-MSCs  
(negative control) 
 
 
1 0.28 
 
 
1 0.38 
 
 
1 0.55 
 
1 0.28 
 
 
1 0.25 
 
 
1 0.19 
 
 
1 0.14 
 
1 1.56 
 
Hepatogenic medium  
 
 
1.81 0.08 
 
 
1.77 0.50 
 
 
1.68 0.34 
 
2.89 0.59 
 
 
1.38 0.15 
 
 
2.70 0.51 
 
 
2.32 0.21 
 
3.62 0.98 
 
Hepatogenic medium 
+ NaB pre-treated 
 
 
1.99 0.32 
 
 
3.37 1.04 
 
 
6.82 0.43 
 
9.46 1.32 
 
 
3.65 0.44 
 
 
3.94 1.32 
 
 
4.94 1.41 
 
7.25 1.39 
 
hHep G2 cells  
(positive control) 
 
 
- 
 
 
- 
 
 
- 
 
141.20 22.94 
 
 
- 
 
 
- 
 
 
- 
 
119.99 12.89 
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Figure 1 A representative validation curve of real time PCR for GAPDH gene. 
(A) The amplification curve for the GAPDH gene. 
(B) The dissociation curve of PCR products of GAPDH gene. 
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Figure 2 A representative validation curve of real time PCR for GATA6 gene. 
(A) The amplification curve for the GATA6 gene. 
(B) The dissociation curve of PCR products of GATA6 gene. 
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Figure 3 A representative validation curve of real time PCR for CXCR4 gene. 
(A) The amplification curve for the CXCR4 gene. 
(B) The dissociation curve of PCR products of CXCR4 gene. 
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Figure 4 A representative validation curve of real time PCR for SOX17 gene. 
(A) The amplification curve for the SOX17 gene. 
(B) The dissociation curve of PCR products of SOX17 gene. 
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Figure 5 A representative validation curve of real time PCR for AFP gene. 
(A) The amplification curve for the AFP gene. 
(B) The dissociation curve of PCR products of AFP gene. 
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Figure 6 A representative validation curve of real time PCR for HNF3β gene. 
(A) The amplification curve for the HNF3β gene. 
(B) The dissociation curve of PCR products of HNF3β gene. 
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Figure 7 A representative validation curve of real time PCR for CK18 gene. 
(A) The amplification curve for the CK18 gene. 
(B) The dissociation curve of PCR products of CK18 gene. 
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Figure 8 A representative validation curve of real time PCR for ALB gene. 
(A) The amplification curve for the ALB gene. 
(B) The dissociation curve of PCR products of ALB gene. 
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Figure 9 A representative validation curve of real time PCR for HDAC1 gene. 
(A) The amplification curve for the HDAC1 gene. 
(B) The dissociation curve of PCR products of HDAC1 gene. 
 
 APPENDIX C  
 
 
Figure 10 Urea standard curve at 430 nm by colorimetric assay. 
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Table 3 Urea production of the differentiated hWJ-MSCs with and without NaB pre-
treatment groups compared to the control (hWJ-MSCs) group at day 3, 10, 
17 and 24 of differentiation (N=3). 
 
                            
                      Day 
 
Conditions 
 
Urea production (ng/ml/10
6
 cell/24 h) 
 
3 
 
10 
 
17 
 
24 
 
hWJ-MSCs  
(Negative control) 
 
 
0.48 0.33 
 
 
0.55 0.43 
 
 
0.54 0.38 
 
0.64 0.51 
 
Hepatogenic medium  
 
 
1.54 0.41 
 
 
2.85 0.16 
 
 
3.82 0.92 
 
4.91 0.46 
 
Hepatogenic medium 
+ NaB pre-treated 
 
 
1.54 0.49 
 
 
2.98 0.20 
 
 
5.64 0.37 
 
6.68 1.26 
 
hHep G2 cells 
 
- 
 
- 
 
- 
 
5.79 1.27 
 
 
 APPENDIX D  
 
 
Figure 11 BSA standard curves at 595 nm by Bradford assay. 
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